First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial

The Lancet, 20 May 2017, Vol.389(10083), pp.2031-2040 [Peer Reviewed Journal]

No full-text

Services for this record
Details
I want this
Notes & Tags

Actions
1. Add to My workspace
2. Remove from My workspace
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. RIS

Notes here allow you and other users to comment and make notes on items, viewable by the whole community.
NB: Please use the Report Catalogue Error form to advise us of catalogue inaccuracies.

Tags allow you and others to define and search on related groups of items.

All tags Cloud

Back to results list

First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial

Searching Remote Databases, Please Wait